- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03749135
Dupilumab in Chronic Spontaneous Urticaria (DUPICSU)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase 2, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Chronic Spontaneous Urticaria Despite H1-antihistamine Treatment.
Study Overview
Status
Intervention / Treatment
Detailed Description
Treatment with Dupilumab has been shown to reduce clinically significant exacerbations and to improve skin symptom control as well as quality of life in moderate to severe atopic dermatitis patients and in moderate to severe asthma patients. It has been approval by European Medicines Agency (EMA) for the treatment of atopic dermatitis patients in September 2017.
Dupilumab is a novel monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in atopic dermatitis and asthma. Considering that CSU and atopic diseases share many common features (e.g. key pathogenic role of mast cells and immunoglobulin E (IgE), itch is a dominant symptom, Th2 dominance), it is reasonable to expect that Dupilumab is beneficial in CSU.
These results suggest that Dupilumab may provide an effective treatment option for patients with insufficient treatment responses to H1-antihistamines exhibiting wheal and flare type skin reactions.
The gold standard treatment of CSU consists of administration of antihistamines. In more than 50% of the patients, symptoms persist with standard dosing of antihistamines. In antihistamine-refractory patients with chronic spontaneous urticaria, the currently only licensed treatment is omalizumab, a monoclonal anti-IgE antibody. In 2014, omalizumab has been licensed for add-on therapy in CSU patients who still have symptoms despite standard-dosed antihistamine treatment. There is, however, still a great medical need for additional treatment options, as 20-40% of patients are still without effective therapy. These patients have no other licensed treatment option and can only be treated off-label with therapeutics with several known safety risks such as Cyclosporine A.
Dupilumab has excellent potential to provide symptom control in CSU. This study will provide additional valuable insights into the therapeutic potential of Dupilumab in improving quality of life in these patients, in addition to managing CSU symptoms.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite University, Berlin, Germany
-
-
Hessen
-
Marburg, Hessen, Germany, 35043
- Universitätsklinikum Giessen und Marburg
-
-
NRW, Germany
-
Münster, NRW, Germany, Germany, 48149
- Hautklinik Universitätsklinikum Münster
-
-
Rheinland-Pfalz, Germany
-
Mainz, Rheinland-Pfalz, Germany, Germany, 55101
- Hautklinik der Universitätsmedizin Mainz Clinical Research Center
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- Universitätsklinikum Carl Gustav Carus
-
Leipzig, Sachsen, Germany, 04103
- Universitätsmedizin Leipzig, Klinik für Dermatologie, Venerologie und Allergologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis: chronic spontaneous urticaria (defined as ongoing disease)
- Patient is informed about study procedures and medications and has given written informed consent before any assessment.
- Patient is able to communicate with the investigator, understands and complies with the requirements of the study.
- Male or Female
- Patient is 18-75 years of age
Patient is diagnosed with moderate to severe CSU and refractory to standard of care treatment at the time of randomization, as defined by the following:
- The presence of itch and hives for more than 6 consecutive weeks at any time prior to enrollment despite current use of H1 antihistamine
- Urticaria activity score UAS7 score (range 0-42) equal or more than 16, 7 days prior to randomization (Day 1)
- CSU diagnosis for 6 months
- Willing and able to complete a daily symptom diary for the duration of the study and adhere to the study visit schedules.
- Patients must not have more than one missing diary entry in the 7 days prior to randomization. Re-screening may be considered.
- Women of childbearing potential have to agree to use an acceptable form of contraception (as determined by the site investigator) and have to continue its use for the duration of the study.
Exclusion Criteria:
- Patients whose urticaria is solely due to inducible urticaria.
- Other diseases with symptoms of urticaria or angioedema, including urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
- Any other active skin disease associated with chronic itching that might confound the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, etc.)
Patients who have received concomitant prohibited medication within the last 3 months prior to screening
- Anti-IgE therapy (e.g. omalizumab)
- Routine (daily or every other day during 5 or more consecutive days) doses of systemic corticosteroids or other immunosuppressants
- Intravenous immunoglobulins
- Biological therapy
- Systemic immunosuppressants
- Live/attenuated vaccines
- Other investigational drug
- History of anaphylactic shock
- Active helminthic parasite infection or treatment of helminthic parasites within 6 months of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dupilumab
Dupilumab (anti-IL4Ra), s.c.
administration
|
anti-IL4-Receptor alpha
|
Placebo Comparator: Placebo Comparator
matching Placebo, s.c.
administration
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urticaria activity score over 7 days (UAS7)
Time Frame: Change from 7 days prior to baseline (Visit (V) 1) to 7 days prior to week 16 (V9)
|
0-42 Points total range over 7 days, higher values equal more disease activity
|
Change from 7 days prior to baseline (Visit (V) 1) to 7 days prior to week 16 (V9)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Itch severity score (ISS7; 0 - no pruritus; 21 - most severe pruritus), hive severity score (HSS7; 0 - no hives; 21 - max. hive severity)
Time Frame: Change from 7 days prior to baseline (Visit (V) 1) to 7 days prior to week 16 (V9)
|
Disease activity scores
|
Change from 7 days prior to baseline (Visit (V) 1) to 7 days prior to week 16 (V9)
|
Global assessment for disease activity
Time Frame: Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)
|
Global assessment for disease activity(physician and patient) by visual analogue scale (VAS; 0 - no pain; 10 - max. amount of pain)
|
Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)
|
urticaria control test (UCT; 16 - complete disease control; 0 - strong symptoms), dermatological quality of life (DLQI; 0 - no impairment; 30 - max. impairment), chronic urticaria quality of life (Cu2-QoL; 23 - no impairment; 115 - max. impairment)
Time Frame: Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)
|
Disease specific quality of life
|
Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)
|
Responder rates (regarding disease activity and quality of live (QoL))
Time Frame: Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)
|
Responder rates (regarding disease activity and quality of live (QoL))
|
Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)
|
rate of angioedema burdened days angioedema activity score (AAS; 0 - lowest disease activity; 15 - highest disease activity) angioedema quality of life (AE-Qol; 0 - no impairment; 100 - worst impairment)
Time Frame: Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)]
|
For patients with concomitant angioedema
|
Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)]
|
Rescue medication use
Time Frame: Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)]
|
Frequency of of how often rescue medication is used
|
Change from 7 days prior to baseline (V1) to 7 days prior to week 16 (V9)]
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marcus Maurer, Prof., Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D-001-01
- 2017-004458-41 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Spontaneous Urticaria
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UriticariaKorea, Republic of, Japan
-
United BioPharmaCompleted
-
United BioPharmaNot yet recruiting
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
United BioPharmaRecruiting
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingChronic Spontaneous UrticariaChina
-
UBP Greater China (Shanghai) Co., LtdNot yet recruitingChronic Spontaneous Urticaria
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States